Bendamustine associated immune suppression and infections during therapy of hematological malignancies

Anat Gafter-Gvili, Aaron Polliack

Research output: Contribution to journalReview articlepeer-review


Bendamustine is being increasingly used in patients with indolent non-Hodgkin lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. This review summarizes available evidence regarDing the effects of bendamustine on the immune system, examines its role in consequent infections as reported in randomized controlled trials, prospective observational investigations, retrospective studies and individual published case reports. Myelosuppression incluDing lymphopenia occurs relatively frequently after therapy with bendamustine. It is mostly CD4 + T cell counts that are suppressed, yet when given in combination with rituximab, both T cell and B cell depletion have been recorded. In addition, hypogammaglobulinemia after bendamustine therapy has also been reported. Variable infection rates have been documented and these include different bacterial, viral and fungal infections. Finally, we also consider issues relating to the use of prophylactic antibiotics in patients receiving the drug.

Original languageEnglish
Pages (from-to)512-519
Number of pages8
JournalLeukemia and Lymphoma
Issue number3
StatePublished - 3 Mar 2016


  • Bendamustine
  • Chemotherapy
  • Hematological malignancies
  • Immune suppression
  • Infections


Dive into the research topics of 'Bendamustine associated immune suppression and infections during therapy of hematological malignancies'. Together they form a unique fingerprint.

Cite this